
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is projected to have a strong launch with the potential for high revenues from their flagship product nomlabofusp due to its positive efficacy data and clinical improvements. Their recent updates have maintained their launch timing for the product and highlighted the potential for successful FDA review and approval. However, there may be a risk of delays or termination of development due to the need for external funding.
Bears say
Larimar Therapeutics is currently not a financially viable company, as it heavily relies on one product, nomlabofusp, for its success. There are also safety concerns regarding potential anaphylaxis reactions from the product and the company's lack of clarity on how to handle them. Additionally, competition from established company Biogen and other emerging gene therapies could further hinder Larimar's success.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares